Table 3.
Asthma pricing—biologics
| Product | Company | Target | Year of market licensing | Price of 6 months treatment | ||
|---|---|---|---|---|---|---|
| USA (USD) | UK (USD) | France (USD) | ||||
| Xolair (omalizumab) | Roche/Novartis | IgE | 2003 | 21.2 K | 17.4 k | 20.5 K |
| Nucala (mepolizumab) | GSK | IL-5 | 2015 | 19.2 K | 7.2 K | 7.3 K |
| Cinqair/Cinqaero (reslizumab) | Teva | IL-5 | 2016 | 17.4 K | 8.4 K | n/a |
| Fasenra (benralizumab) | AstraZeneca / Kyowa Hakko Kirin | IL-5R | 2017 | 19.2 K | 16.6 K | 14.4 K |
| Dupixent (dupilumab) | Sanofi-Genzyme Regeneron |
IL-4 IL-13 |
2018 | 21.1 K | 10.8 K | 10.4 K |
n/a, not applicable
Sources: RedBook Online, accessed Jan 2020 [94]; MIMS Online, accessed Jan 2020 [95]; Akuthota and Weller UpToDate, 2018 [96]
Note: The US price is the wholesale acquisition cost (WAC), which is the manufacturer's list price for a product when sold to wholesalers. The WAC may not represent actual transaction prices and does not include discounts or rebates Assumptions: Exchange rate of £1:$1.30, €1:$1.20
US Prescribing Information and European SPCs; RedBook Online, accessed Feb 2019 [94]; MIMS Online, accessed Feb 2019 [95]
Xolair dose depends on body weight and pre-treatment IgE serum levels. The US price is the wholesale acquisition cost (WAC), which is the manufacturer’s list price for a product when sold to wholesalers. The WAC may not represent actual transaction prices and does not include discounts or rebates Assumptions: (1) average body weight of 75 kg; (2) no sharing of vials between patients; (3) exchange rate of £1:$1.29, XE, com, Feb 2019